Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing: 1–36
Headlines: 115
Sources here: 3
Companies here: 7

Current section Austria Drug Manufacturers - General news Latest headline 14:50, 14 August 2026

Latest14:50 · 14 August 2026

finance.yahoo.com Earnings

3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold

The drug and biotechnology sector has had a strong recovery so far in 2026, driven by innovation, robust quarterly performances, optimistic full-year outlooks, positive regulatory updates and a major wave of M&A activity. However, it faces its share of headwinds like slower-than-expected launches of newer therapies, looming patent expirations for several blockbuster drugs and ongoing policy and pricing …

Provider-linked mention 🇦🇹 Austria

Read at finance.yahoo.com

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

Just inNext headlines

13:31 14 Aug 2026

seekingalpha.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s

[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer’s disease through positron emission tomography (PET). Specifically, the approval allows the …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

13:00 14 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains

While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

12:35 14 Aug 2026

nasdaq.com Market update Provider-linked mention 🇦🇹 Austria

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's holds 338 stocks across the broader healthcare sector. …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

06:49 14 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call

5 Revealing Analyst Questions From Eli Lilly's Q2 Earnings Call Eli Lilly's second quarter was marked by a positive market reaction, despite the company missing Wall Street's revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

00:38 14 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇹 Austria

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +23.7%

00:07 14 Aug 2026

finance.yahoo.com Market update Main company 🇦🇹 Austria

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +52.0%

22:33 13 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +23.7%

22:12 13 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Product Image (Photo: Bristol Myers Squibb)ZENBEXUS™ (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment …

BMYS main company

Sharemaestro market context Trend signal active 52 weeks +41.2%

21:07 13 Aug 2026

finance.yahoo.com Analyst action Main company 🇦🇹 Austria

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +59.8%

19:38 13 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:48 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:48 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:32 13 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:20 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

16:54 13 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2

The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

16:12 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

15:30 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications

WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

15:26 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

15:05 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

15:00 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

14:52 13 Aug 2026

finance.yahoo.com Analyst action Main company 🇦🇹 Austria

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +52.0%

14:42 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

14:15 13 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

13:01 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

This Healthcare Services Stock Has 37% Upside

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

11:20 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?

Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

00:41 13 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +59.8%

20:58 12 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

19:36 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

18:29 12 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:24 12 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:11 12 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇦🇹 Austria

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

18:08 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

17:54 12 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇹 Austria

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY …

LLYC main company

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

17:11 12 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +52.0%

16:10 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%